In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
News|Podcasts|December 9, 2025
ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR Clinical on the biggest opportunities to advance site operations and collaboration, and highlight new long-term data supporting earlier use of Carvykti in relapsed or refractory multiple myeloma.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- A new feature
article examines how robust relational governance between eCOA vendors and sponsor–CRO teams is becoming essential for fast, high-quality study launches. Clear communication frameworks, empowered customer success teams, and continuous learning cycles are helping organizations reduce issues, improve data quality, and accelerate trial startup across entire portfolios. - In a new
video interview from the 2025 Veeva R&D and Quality Summit, AMR Clinical’s Nancy Cleverley outlines the biggest opportunities to strengthen site operations across its 30-site network. She describes how sponsors and CROs can reduce burden, support better participant experiences, and enable easier data sharing and real-time collaboration as trial execution models continue to evolve. - And new CARTITUDE-4 trial
data shows that earlier use of Johnson & Johnson’s Carvykti is producing durable, treatment-free remissions lasting well beyond 30 months for many relapsed or refractory multiple myeloma patients. The findings build on real-world evidence from more than 9,000 treated patients and signal a meaningful shift toward deploying CAR-T therapy sooner in the treatment pathway.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
3
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5